Recent News
Read ArticleManzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab.
2025 Lancet review https://t.co/Qbwup6QxZK of Osteoarthritis did not mention/endorse Rx w/ platelet rich plasma (PRP) prompting several letters of protest. Read the authors response: Despite the popularity of PRP, there are few PBO controlled high quality studies to prove its https://t.co/7pCZV9CHfJ
Links:
Dr. John Cush @RheumNow ( View Tweet)
NJ Senate (Senate Bill No. 3560) has voted to permite Physician Assistans to enter the Interstate Physician Assistant Licensure Compact, designed to streamline PA licensing to work in multiple states https://t.co/VE1DdWuFwM https://t.co/szJzShVAaz
Links:
Dr. John Cush @RheumNow ( View Tweet)
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/OOctcfI1sT
Dr. John Cush @RheumNow ( View Tweet)
Systematic review of Apremilast in soriasis and Psoriatic Arthritis: 28 RCTs involving 6825 patients. Efficacy ( PASI 75 and ACR 20) observed at APR 30 mg or 20 mg bid (RR > 2) & both doses did not affect CRP levels. GI side effx most common (see figure) https://t.co/YqfaWPvmTm https://t.co/z8PfJqp0CJ
Links:
Dr. John Cush @RheumNow ( View Tweet)
DANFLU-2 RCT of 332 438 elderly (43 881 w/ diabetes) tested high (HD-IIV) vs standard dose SD-IIV) flu vaccine. HD-IIV signif. reduced cardioresp., CV, CHF, influenza, hospitalizations vs SD-IIV, irrespective of DM status. Similar results previously seen in a Canadian RA pop. https://t.co/GGZPThoHrs
Dr. John Cush @RheumNow ( View Tweet)
QD Clinic: Tophi Tales: Management of Uncontrolled Gout
Daric Mueller, PA-C and Andrew Sulich, MD, St. Clair Shores, MI, present this QD Clinic: Tophi Tales: Management of Uncontrolled Gout. This QD Clinic is presented as part of RheumNow's "Mission: APP Partners in Care" https://t.co/7JTbC0223I
Dr. John Cush @RheumNow ( View Tweet)
GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis
Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w
Dr. John Cush @RheumNow ( View Tweet)
2025 Rheumatologists, In Memorium
In 2025, rheumatology lost many of its most influential clinicians, mentors, and colleagues. This honor roll recognizes those who cared for countless patients, shaped generations of rheumatologists, and left a lasting legacy in our field. As Dr. https://t.co/MMa670vsoH
Dr. John Cush @RheumNow ( View Tweet)
J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn blocker that reduces AutoAbs & B cell activity. Study met its 24 wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://t.co/KMseKyGirt
Dr. John Cush @RheumNow ( View Tweet)
Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty.
Register: https://t.co/MVgXnacU5q https://t.co/7ajH7Ry0Uj
Links:
Dr. John Cush @RheumNow ( View Tweet)
“The practice of medicine is an art, not a trade; a calling, not a business; a calling in which your heart will be exercised equally with your head. – Sir William Osler
Dr. John Cush @RheumNow ( View Tweet)
Anti-mitochondrial M2 Ab (AMA-M2) in 987 IIM pts-- 55 (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of polymyositis (56% vs 23.5%), GGT, alk phos levels, & 3 fold more cardiac involvement (60 vs 13%) (arrhythmias, CHF, pulm HTN (31-56%), but no effect on survival https://t.co/8fQzgRfHr4
Dr. John Cush @RheumNow ( View Tweet)
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis
The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/8VNQtP3Izj
Dr. John Cush @RheumNow ( View Tweet)
UK study of 1846 RA pts starting a b/tsDMARDs, ~30% on steroids & majority (2/3) continued use over the first year of new novel treatment. This suggests these aer either severe RA pts or that we are not vigilant in limiting/weaning/stopping steroids in RA patients - which is it? https://t.co/TrAktincKT
Dr. John Cush @RheumNow ( View Tweet)
Japan retrospective study of 38 RA pts who developed MTX assoc lymphoproliferative disorder (LPD) - 22 w/ spontaneous regression (SR) vs 16 non-SR (w/ 5 deaths). non-SR Pt had higher LDH levels at Dx & lower lymphocyte recovery 1 mo. post MTX withdrawal & higher mortality risk https://t.co/TRizVwP2BQ
Dr. John Cush @RheumNow ( View Tweet)
Subcutaneous Anifrolumab Effective in Lupus
A new study published in Arthritis & Rheumatology demonstrates that subcutaneous administration of anifrolumab provides efficacy comparable to intravenous administration, offering a promising alternative for at-home care of patients https://t.co/KgBC8vJHuB
Dr. John Cush @RheumNow ( View Tweet)
2026 Resolutions (1.9.2026)
Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!
Read Article
2025 Rheumatologists, In Memorium
In 2025, rheumatology lost many of its most influential clinicians, mentors, and colleagues. This honor roll recognizes those who cared for countless patients, shaped generations of rheumatologists, and left a lasting legacy in our field. As Dr.
Dr. John Cush @RheumNow ( View Tweet)
DERM on RheumNow Podcast (December 2025)
https://t.co/icOauEOhLP https://t.co/eMt40WFiFD
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
2026 Resolutions (1.9.2026)
DERM on RheumNow Podcast (December 2025)
Comorbidity and Health Management-
Telling You Where to Go (12.19.2025)
Therapeutic Updates
Advancing the Treatment Landscape for Pediatric Psoriatic Disease
Sponsored by Johnson & Johnson
Learn more about a treatment offering pediatric patients 6 years and older who also weigh at least 40 kg, and their physicians and adult caregivers, an option that may improve skin clearance for moderate to severe plaque psoriasis or treat active psoriatic arthritis, collectively known as psoriatic disease.
Read Post
Underserved and Under-treated
RheumNow
Watch our Underserved and Under-Treated series as part of this month's Mission: APP Partners in Care campaign. Now available: Pain Management and Workforce & APPs
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
